Part:BBa_K3245010
Part Name MccB17
Contents
Description:
This part is a full functional gene cluster that produces microcin B17 ( MccB17 ), a kind of antimicrobial peptide. MccB17 belongs to class I microcin, one of the toxic peptides secreted by enterobacteria ( E.coli in this case ). It only works when protease TId D/E ( PmbA ) complex exists which is able to remove the leading peptide to produce mature microcin. The compound displayed antibacterial activity on some strains of E. coli, Enterobacter, Pseudomonas and Shigella.
Usage and biology:
MccB17 inhibits DNA replication by binding with DNA gyrase and induces DNA double-strand cleavage and degradation. The specificity of target bacteria depends on the properties of different gyrases and homologous resistance genes. Microcin genesis requires structural gene ( McbA ), synthase ( McbBCD ) and protease ( TldD/E, outside the original plasmid ). McbE and McbF control efflux, and McbG is responsible for immunity. We introduced this gene cluster to enhance Nissle’s competitiveness and reduce risk of illness caused by some opportunistic pathogens.
Design:
We keep most of the original sequence but adjust several codons to meet RFC10 standard.
Figure 1. Details of The MccB17 gene cluster. It shows the McbA gene product and how it is processed by the microcin synthase (McbBCD) and protease (TldD/E). McbE and McbF control efflux, and McbG is responsible for immunity.
Characterization:
Due to the toxicity of MccB17, its concentration in cells is very low and it’s hard to gain precise data without purification. We used soft agar double-layer technique to measure the inhibition zone and compared the result with common antibiotics such as ampicillin and kanamycin. However, Nissle with MccB17 shows faint effect of inhibiting E. coli DH10B. Further measurement is needed.
Characterized by Fudan in 2020
We divided this part into two parts: McbABCD and McbEFG.
Method
In order to prove that McbABCDEFG does have an effective antibacterial effect as well as McbEFG can protect the engineered bacteria themselves and help the secretion of antimicrobial peptides more effectively, we designed the following experiment:
We mixed WT E.coli (expressing GFP driven by plac) and E.coli with mcbABCD-mcbEFG-ptetR in different ratios (5:7 20:7 50:7), and measured the OD value of the bacteria two hours after adding an inducer, which can be used to reflect the antibacterial effect of antimicrobial peptides. We followed the same method as above to mix WT E. coli and E.coli with merely mcbABCD, induce and measure the OD value.
Results
Figure1. MEFL/particle for different Px and PxAD when the ratio of mixure(WT:Px=5:7)
Figure2. MEFL/particle for different Px and PxAD when the ratio of mixure(WT:Px=20:7)
Figure3. MEFL/particle for different Px and PxAD when the ratio of mixure(WT:Px=50:7)
The result shows that E.coli with mcbABCD-mcbEFG-ptetR can more effectively inhibit the metabolism of other bacteria than those merely with mcbABCD in each group. With mcbEFG, E.coli are able to export antimicrobial peptides more effectively and supposed to have better immunity themselves so as to affect the surrounding WT’s metabolism(the expression of GFP), and better survive in the environment. While comparing to the control group, we can also see a significant decrease in the GFP expression result when there are E.coli with mcbABCD-mcbEFG-ptetR or mcbABCD, which indicates that the antimicrobial peptide(mccb17) encoded by mcbABCD does have a strong restraining effect on other microbial. That is to say, we can indeed increase the competitiveness of engineered bacteria by turning on the McbEFG gene, and turn off the McbEFG gene to block the antibacterial effect of antimicrobial peptides. It is worth noting that when the mixing ratio of WT E. coli and McbABCDEFG-expressing bacteria is 50:7, the OD values of each group are very close to those of the control group (only induced WT E. coli). This shows that when the concentration of the engineered bacteria is very low, the antimicrobial peptides are difficult to exert antibacterial effect and the engineered bacteria have no competitive advantage.
Reference
Collin F, Maxwell A. The Microbial Toxin Microcin B17: Prospects for the Development of New Antibacterial Agents. J Mol Biol. 2019;431(18):3400–3426. doi:10.1016/j.jmb.2019.05.050
S. Duquesne, D. Destoumieux-Garzón, J. Peduzzi, S. Rebuffat. Microcins, gene-encoded antibacterial peptides from enterobacteria
Nat. Prod. Rep., 24 (2007), p. 708, 10.1039/b516237h
| None |